Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Exercise & healthspan
Research brief

Multi-omics signature in vervet leg muscle: middle-aged versus older females

In vastus lateralis muscle of female vervet monkeys, a multi-omics signature distinguished middle-aged animals with normal gait speed from older animals with declining gait speed. [1]

Automatic summary · not editorially reviewed

The key findings

  1. Vastus lateralis muscle from female vervet monkeys was compared between middle-aged animals with normal gait speed and older animals with declining gait speed. [1]

  2. Integrating transcriptome, miRNome and methylome data yielded a signature that sharply distinguished the two groups. [1]

  3. The findings are described as associated with impaired muscle function during aging and as potential mechanisms and targets, not proven causes. [1]

The source at a glance

Study type / format
Abstract of a multi-omics animal study
Population / context
Female vervet monkeys (Chlorocebus aethiops sabaeus); middle-aged with normal gait speed versus older with declining gait speed.
Summary based on
Study abstract
Publication status
Preprint · peer-review status not confirmed
Original publication
October 1, 2026

Vervet leg muscle: middle-aged versus older females

The researchers studied the vastus lateralis muscle, a thigh muscle, from female vervet monkeys (Chlorocebus aethiops sabaeus). They compared middle-aged animals with normal gait speed against older animals whose gait speed was declining. The abstract links age-related loss of skeletal muscle function, often seen as slower gait speed, to frailty and loss of independence.

Supporting source [1]

Transcriptome, miRNome and methylome combined

The team examined coordinated changes across three molecular layers: the transcriptome, the miRNome and the methylome. Integrating these layers produced a signature that sharply separated the two groups. It involved miR-181a-5p, miR-320b and miR-425 controlling SYNCRIP, miR-193b-3p regulating MCL1 and PLAU, a multi-omic network governing ZNF274 and ANP32E, and altered mRNA levels such as VEZT. Functional annotation linked the miRNA signatures, with inverse expression of their mRNA targets, to skeletal muscle biology, metabolism and possible immune-inflammation mechanisms.

Supporting source [1]

Abstract-only scope of the vervet muscle findings

The abstract describes an interconnected network of epigenetic, post-transcriptional and transcriptional alterations associated with impaired muscle function during aging. It presents these molecules as potential mechanisms and targets, not as proven causes or tested interventions. The abstract does not report sample sizes, follow-up or effect estimates, and the full text was not reviewed. These are animal and molecular findings, not evidence of human lifespan or muscle benefit.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. Sample sizes, follow-up and effect estimates are not reported. Animal and molecular associations do not establish human benefit.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Integrative Multi-Omics Analysis Reveals Molecular Signatures of Age-Related Decline in Vervet Leg Skeletal Muscle

Patel M, Rudasi EV, Frye B, Negrey JD, Cox LA, Li G, Jorgensen M, Register TC, Kavanagh K, Shively CA, Quillen EE. · europepmc.org · October 1, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    contrasting middle-aged animals with normal gait speed
  2. Finding 2 ↑

    a molecular signature that sharply distinguishes these
  3. Finding 3 ↑

    associated with impaired muscle function during aging

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…